AIDS Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AIDS Therapies
Improved Dosing Formulations For Investigational Drug In Development
November 19th, 2001
Progenics Pharmaceuticals, Inc., announced the initiation of a collaboration with Formatech, Inc., Andover, Massachusetts, to develop improved product formulations for PRO 542, an investigational drug currently in Phase II clinical testing for the treatment of HIV infection. The announcement accompanies the release of new findings that PRO 542 possesses potent antiviral activity when given by multiple routes of administration, including subcutaneous injection. The new studies demonstrated that PRO 542 reduced viral load to undetectable levels in a well-recognized animal model of HIV infection and may point the way towards simplified dosing regimens in man. ...
Source: AIDS Weekly (2001-11-19)
|
